Free Trial

LAVA Therapeutics (LVTX) Competitors

LAVA Therapeutics logo
$1.43 -0.03 (-2.05%)
Closing price 07/25/2025 03:50 PM Eastern
Extended Trading
$1.46 +0.03 (+1.75%)
As of 07/25/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LVTX vs. IMRX, MOLN, THTX, TNYA, LIMN, IKT, LXEO, CGEN, LYEL, and NKTX

Should you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Immuneering (IMRX), Molecular Partners (MOLN), Theratechnologies (THTX), Tenaya Therapeutics (TNYA), Liminatus Pharma (LIMN), Inhibikase Therapeutics (IKT), Lexeo Therapeutics (LXEO), Compugen (CGEN), Lyell Immunopharma (LYEL), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

LAVA Therapeutics vs. Its Competitors

Immuneering (NASDAQ:IMRX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, Immuneering and Immuneering both had 1 articles in the media. LAVA Therapeutics' average media sentiment score of 1.87 beat Immuneering's score of 0.93 indicating that LAVA Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Immuneering Positive
LAVA Therapeutics Very Positive

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LAVA Therapeutics' return on equity of -86.38% beat Immuneering's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -119.22% -99.22%
LAVA Therapeutics N/A -86.38%-34.12%

Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Immuneering currently has a consensus price target of $13.25, suggesting a potential upside of 226.35%. LAVA Therapeutics has a consensus price target of $3.17, suggesting a potential upside of 121.45%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than LAVA Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
LAVA Therapeutics
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

LAVA Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuneering$320K456.62-$61.04M-$1.96-2.07
LAVA Therapeutics$11.98M3.14-$25.11M-$1.04-1.38

Summary

LAVA Therapeutics beats Immuneering on 8 of the 14 factors compared between the two stocks.

Get LAVA Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LVTX vs. The Competition

MetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$38.41M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-1.3821.1828.1020.05
Price / Sales3.14286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book1.358.378.665.87
Net Income-$25.11M-$55.19M$3.25B$258.55M
7 Day Performance0.70%5.88%4.22%3.73%
1 Month Performance9.58%17.33%10.51%11.75%
1 Year Performance-30.92%4.42%34.40%18.03%

LAVA Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LVTX
LAVA Therapeutics
2.3803 of 5 stars
$1.43
-2.1%
$3.17
+121.4%
-32.2%$38.41M$11.98M-1.3860Positive News
IMRX
Immuneering
3.1361 of 5 stars
$4.24
+2.7%
$13.25
+212.5%
+230.1%$148.62M$320K-2.1660Gap Up
MOLN
Molecular Partners
2.5584 of 5 stars
$3.79
+5.4%
$12.00
+216.3%
-31.5%$145.15M$5.65M-1.98180News Coverage
THTX
Theratechnologies
N/A$3.14
flat
N/A+119.4%$144.38M$85.87M-16.53140Positive News
TNYA
Tenaya Therapeutics
3.9387 of 5 stars
$0.86
-2.3%
$6.25
+629.6%
-79.1%$142.68MN/A-0.74110Positive News
LIMN
Liminatus Pharma
N/A$5.58
+3.0%
N/AN/A$141MN/A0.00N/ANews Coverage
Gap Down
IKT
Inhibikase Therapeutics
1.4861 of 5 stars
$1.88
+2.2%
$6.50
+245.7%
+10.6%$139.76MN/A-0.706News Coverage
LXEO
Lexeo Therapeutics
2.0379 of 5 stars
$3.96
-4.6%
$16.60
+319.2%
-65.0%$137.77M$650K-1.2058
CGEN
Compugen
1.4458 of 5 stars
$1.51
-1.9%
$4.00
+164.9%
-13.1%$137.43M$27.86M-9.4470
LYEL
Lyell Immunopharma
2.5105 of 5 stars
$9.49
+2.7%
$15.00
+58.1%
-61.9%$136.83M$60K-0.38270News Coverage
Gap Up
NKTX
Nkarta
1.768 of 5 stars
$1.92
+0.5%
$14.33
+646.5%
-68.7%$135.53MN/A-1.27140Positive News

Related Companies and Tools


This page (NASDAQ:LVTX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners